Replies to post #242370 on Elite Pharmaceuticals Inc (ELTP)

[ARbigguy1]

Shark, great link, Elite - "this is a biotechnology company with all the reward of a development stage entity targeting a big indication, but only a fraction of the risk."

That is an excellent description of Elite!

[namtae]

WOW, another silly, biased (admittedly) report on Elite from insider financial lol

For sophisticated investors, its does more harm than good for Elite

No, this one’s got two sides to its operations – one that resembles the just mentioned exploratory pipeline structure, and another that is a revenue generating generic drug manufacturing arm.

Exactly the last thing a sharp investor wants to see as Elite flip/flops from a new drug developer to a generic manufacturer, thereby associating itself with the greatly reduced valuation model of a generic manufacturer

This two pronged structure is important, as it means the company can fund a large portion of its own development costs with the generic business. That removes the potential for dilution on a shareholder’s exposure

Not exactly sure how that last line is worded however, is it suggesting generics removes the potential for dilution?? LOL I&O now well over 900,000,000!!!!

Consolidated revenues for the third quarter of Fiscal 2017 were $2.3 million, a 6% increase on a year-on-year basis.

As is the case with most PENNY STOCK "so-called analysts" they take a development stage company (still after 25 years) and compare year2year financials instead of sequential quarterly numbers, the TRUE MEASURE of progress... As we know, the last 2 quarters have shown a DECREASE in Generic manufacturing revs

Development costs, which were primarily attributable to the company’s ongoing development of its lead abuse deterrent asset – SequestOx – came in at $1.5 million, meaning the company is generating around $800K more in revenues than it is spending on development. That’s not something that can often be said for a company at this end of the market, in this space.

The above observation is about as irrelevant as one can be. The comparison of REVENUES to DEVELOPMENT COSTS?? lol This is sophomoric!! There is absolutely no correlation between the two. Perhaps something like comparing Generics free cash flow to development costs would make sense..but it doesnt in Elites case lol

This report should bump Elite shares up .001 Monday morning...briefly

[snupoled]

Shark,

thanks, sipping tea as I read and ponder what this means
for 2018

old snup ponders,

sequest ox check
pipe lone check

generics hmm, decrease need for more, and more, and more dilution
into the future, wow most start ups , biotechs have R+D and no
revenues with us it is different.

hmm, one anda each Q thru-out 2017, hmmm, as months tick by we
will hear more and more regarding ongoing preparations to launch
4 drugs with sungen, at least two are not adts. hmm these can
get us to a buck in and of themselves.

hell yeah dd king Queens on our board can wait for 2018
for permenant wealth transfer,

poison pill means big pharma play fair with buy out offer one of

article's conclusion dots connected by old snup from fly over

countys

LOCK THEM DOWN, LOCK THEM DOWN, LOCK HER UP OOOPS, LOCKED AND
LOADED

G.T.C order, with All or none placed with broker at much higher
price.

Our ceo will still be with Elite come tuesday morning

He will see us thru and work diligently until we succeed

man,

that short synopsis of elite pharmaceuticals should be stickied.

partnership,
buyout,
humanwell speaks
epic/eltp alliance
sales/marketing teams in place , awaiting marching orders
road trips, docs CEU's will again be talked about

eltp will get mainstream print, audio, interviewd soon enough

LOCKED DOWN AND LOADED
RAISE EM ELITE STERS
^^^^^^^
!!!!!!! SNUP DAWG OLED

[Gman24]

Nice article sharkey1... anxiously tuning in to the CC tomorrow .. sure would be nice to see a PR in morning leading into it. GLTA